lefitolimod mgn 1703 (MOLOGEN Inc)
90
Structured Review
MOLOGEN Inc
lefitolimod mgn 1703
Lefitolimod Mgn 1703, supplied by MOLOGEN Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgn-1703/mgn1703/pmc10935485-33-1-5
Average 90 stars, based on 1 article reviews
Lefitolimod Mgn 1703, supplied by MOLOGEN Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgn-1703/mgn1703/pmc10935485-33-1-5
Average 90 stars, based on 1 article reviews
lefitolimod mgn 1703 - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Small-molecule agents for cancer immunotherapy"
Article Title: Small-molecule agents for cancer immunotherapy
Journal: Acta Pharmaceutica Sinica. B
doi: 10.1016/j.apsb.2023.12.010
Figure Legend Snippet: Small-molecule agents under clinical development in immuno-oncology.
Techniques Used:
Figure Legend Snippet: Small-molecule agents in combinational therapies.
Techniques Used: Vaccines, Infection
Related Articles
Sandwich ELISA:Article Title: Discontinued drugs in 2011: oncology drugs. Article Snippet: sonline.com/Plan/ViewAbstract.aspx?sKey=1ee9fbdb-aspx?sKey=1ee9fbdb- Article Title: Targeting Toll-like receptors: emerging therapeutics? Article Snippet: DATABASES OMIM: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM actinic keratosis | inflammatory bowel disease UniProtKB: http://ca.expasy.org/sprot iNOS | MAL | MYD88 | SHIP-1 | TRAM | TRIF | ClinicalTrials.gov: http://clinicaltrials.gov/ NCT00729053 | NCT00633529 | NCT00719199 | NCT00251394 | NCT00403052 | NCT00091208 | NCT00675727 | NCT00728936 | NCT00990938 | NCT00823862 | NCT00603811 | NCT00688415 | NCT00770003 | NCT00999466 | NCT00547014 | NCT00334828 | NCT00633477 FURTHER Article Title: Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) Article Snippet: In one embodiment of the invention the TLR9 agonist used in the combination treatment of the present invention is a oligodeoxynucleotides based CpG motif-containing Article Title: Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist Article Snippet: In one embodiment of the invention the TLR9 agonist of the invention is a oligodeoxynucleotides based CpG motif-containing Article Title: Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof Article Snippet: In addition, in the present invention, the toll-like receptor 9 agonist may be, but is not limited to, an oligodeoxynucleotide based on CpG motif-containing Article Title: Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) Article Snippet: Several TLR9 agonist are known and currently developed in clinical testing Agatolimod (tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs; Pfizer) GNKGI68 (CpG ODN; SBI Biotech), IMO-2055 (synthetic oligonucleotide containing unmethylated CpG dinucleotides; Idera Pharmaceuticals), Isolation:Article Title: Discontinued drugs in 2011: oncology drugs. Article Snippet: sonline.com/Plan/ViewAbstract.aspx?sKey=1ee9fbdb-aspx?sKey=1ee9fbdb- Article Title: Targeting Toll-like receptors: emerging therapeutics? Article Snippet: DATABASES OMIM: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM actinic keratosis | inflammatory bowel disease UniProtKB: http://ca.expasy.org/sprot iNOS | MAL | MYD88 | SHIP-1 | TRAM | TRIF | ClinicalTrials.gov: http://clinicaltrials.gov/ NCT00729053 | NCT00633529 | NCT00719199 | NCT00251394 | NCT00403052 | NCT00091208 | NCT00675727 | NCT00728936 | NCT00990938 | NCT00823862 | NCT00603811 | NCT00688415 | NCT00770003 | NCT00999466 | NCT00547014 | NCT00334828 | NCT00633477 FURTHER Article Title: Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) Article Snippet: In one embodiment of the invention the TLR9 agonist used in the combination treatment of the present invention is a oligodeoxynucleotides based CpG motif-containing Article Title: Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist Article Snippet: In one embodiment of the invention the TLR9 agonist of the invention is a oligodeoxynucleotides based CpG motif-containing Article Title: Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof Article Snippet: In addition, in the present invention, the toll-like receptor 9 agonist may be, but is not limited to, an oligodeoxynucleotide based on CpG motif-containing Article Title: Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) Article Snippet: Several TLR9 agonist are known and currently developed in clinical testing Agatolimod (tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs; Pfizer) GNKGI68 (CpG ODN; SBI Biotech), IMO-2055 (synthetic oligonucleotide containing unmethylated CpG dinucleotides; Idera Pharmaceuticals), Gradient Centrifugation:Article Title: Discontinued drugs in 2011: oncology drugs. Article Snippet: sonline.com/Plan/ViewAbstract.aspx?sKey=1ee9fbdb-aspx?sKey=1ee9fbdb- Article Title: Targeting Toll-like receptors: emerging therapeutics? Article Snippet: DATABASES OMIM: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM actinic keratosis | inflammatory bowel disease UniProtKB: http://ca.expasy.org/sprot iNOS | MAL | MYD88 | SHIP-1 | TRAM | TRIF | ClinicalTrials.gov: http://clinicaltrials.gov/ NCT00729053 | NCT00633529 | NCT00719199 | NCT00251394 | NCT00403052 | NCT00091208 | NCT00675727 | NCT00728936 | NCT00990938 | NCT00823862 | NCT00603811 | NCT00688415 | NCT00770003 | NCT00999466 | NCT00547014 | NCT00334828 | NCT00633477 FURTHER Article Title: Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) Article Snippet: In one embodiment of the invention the TLR9 agonist used in the combination treatment of the present invention is a oligodeoxynucleotides based CpG motif-containing Article Title: Method of treating cancer by administering CSF-1R antibodies and a TLR9 agonist Article Snippet: In one embodiment of the invention the TLR9 agonist of the invention is a oligodeoxynucleotides based CpG motif-containing Article Title: Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof Article Snippet: In addition, in the present invention, the toll-like receptor 9 agonist may be, but is not limited to, an oligodeoxynucleotide based on CpG motif-containing Article Title: Method of treating cancer in a patient by administering an antibody which binds colony stimulating factor-1 receptor (CSF-1R) Article Snippet: Several TLR9 agonist are known and currently developed in clinical testing Agatolimod (tricosasodium salt of a synthetic 24-mer oligonucleotide containing 3 CpG motifs; Pfizer) GNKGI68 (CpG ODN; SBI Biotech), IMO-2055 (synthetic oligonucleotide containing unmethylated CpG dinucleotides; Idera Pharmaceuticals), |